Feasibility and safety of bispecific antibodies outpatient model in triple-refractory multiple myeloma patients in two Italian centers
Paola Boggione(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Federico Monaco(Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo), Gianluca Gaïdano(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Gloria Margiotta Casaluci(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Marco Ladetto(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Clara Deambrogi(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Samir Mouhssine(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Abdurraouf Mokhtar Mahmoud(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Wael Alessa(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Lorenzo De Paoli(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Golsa Farazmand(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Riccardo Moia(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”)
Cited by 1
Related Papers
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2015|920
Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2017|736
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
|The Lancet Haematology|2020|553
The coding genome of splenic marginal zone lymphoma: activation of <i>NOTCH2</i> and other pathways regulating marginal zone development
|The Journal of Experimental Medicine|2012|378